MDT

Medtronic Plc

Exchange: NYSESector: HealthcareIndustry: Medical Devices

As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery. About Medtronic Bold thinking. Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Did you know?

Free cash flow has been growing at -2.1% annually.

Current Price

$78.30

-2.13%

GoodMoat Value

$53.32

31.9% overvalued

Profile

Valuation (TTM)

Market Cap$100.38B

P/E21.76

EV$131.44B

P/B2.09

Shares Out1.28B

P/Sales2.83

Revenue$35.48B

EV/EBITDA12.87

Medtronic Plc (MDT) Financial Statements

GoodMoat Analysis

Based on data as of March 26, 2026

Medtronic exhibits a mixed financial profile for a value investor, with moderate revenue growth and a healthy dividend, but key quality metrics like ROE and FCF conversion appear weak relative to framework standards. The balance sheet is leveraged, and the valuation based on the GoodMoat target suggests caution.

Read full analysis

Medtronic's financial health presents a nuanced picture. On growth, the 8.7% YoY revenue growth is positive but falls short of the framework's 'sustained above 20%' benchmark for high-growth companies, indicating a more mature trajectory. The 17.8% operating margin suggests decent profitability, though without gross margin data, a full margin trend assessment is limited. Free cash flow generation, with a 4.6% FCF yield, is positive but its conversion rate from EBITDA cannot be verified from the provided data; the framework favours a rate above 90%. The balance sheet shows moderate leverage with a Debt/Equity ratio of 0.59, which is manageable but not the substantial net cash position preferred. A critical quality indicator is the 9.6% Return on Equity (ROE), which is below the framework's high-quality threshold of 15-20% for Return on Invested Capital (ROIC), suggesting capital is not being deployed for exceptionally high returns. The dividend yield of 3.19% is a stable income component. Overall, the financial quality is adequate but not strong, with several metrics not meeting the high benchmarks for a 'High Quality' rating in the framework. The significant divergence between the current price and the GoodMoat Target price underscores a valuation concern that requires careful scrutiny. Analysis based on data as of 2024-05-15.

MDT Financial Data

EBITDA$9.33B

Revenue (TTM)$35.48B

Gross Profit (TTM)$23.01B

Gross Margin—

Operating Margin17.76%

ROE9.61%

ROA5.03%

Debt/Equity0.59

Current Ratio1.85

FCF$5.18B

FCF Yield5.17%

Piotroski F-Score—

Rev/Share (TTM)$27.68

50-Day MA$87.58

200-Day MA$92.88

Shares Outstanding1.28B

MDT Computed Insights

FCF$5.18B

FCF Growth Rate-2.06%

EPS Growth (CAGR)0.11%

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

MDT Financial Statements & Data

Medtronic Plc (MDT) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Medtronic Plc's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $35.48B. Gross profit (TTM) is $23.01B. EBITDA is $9.33B. Earnings per share (EPS) is $3.61. The P/E ratio is 21.76. Market capitalization is $100.38B.

Free cash flow (FCF) is $5.18B. FCF growth rate is -2.06%. EPS growth CAGR is 0.11%. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Medtronic Plc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.